Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma

Derek A. Wainwright, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Glioblastoma is an aggressive primary brain cancer. Given our interest in novel immunotherapies, we have recently shown that inhibiting CTLA-4, PD-L1 and IDO results in a dramatic survival advantage in mice with brain tumors. Our preclinical study supports the rapid translation of this approach into phase I clinical trial.

Original languageEnglish (US)
Article numbere28927
JournalOncoImmunology
Volume3
Issue number5
DOIs
StatePublished - 2014

Keywords

  • Glioblastoma
  • Immunosuppression
  • Immunotherapy
  • Metabolism
  • Tryptophan

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Ménage à trois: Sustained therapeutic anti-tumor immunity requires multiple partners in malignant glioma'. Together they form a unique fingerprint.

Cite this